Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v4-FR
Language French French
Date Updated 2020-06-25 2020-06-25
Drug Identification Number 02409275 02409275
Brand name DOXORUBICIN HYDROCHLORIDE INJECTION DOXORUBICIN HYDROCHLORIDE INJECTION
Common or Proper name DOXORUBICIN INJ 200MG/100ML DOXORUBICIN INJ 200MG/100ML
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients DOXORUBICIN HYDROCHLORIDE DOXORUBICIN HYDROCHLORIDE
Strength(s) 2MG 2MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVESICAL INTRAVENOUS INTRAVESICAL INTRAVENOUS INTRAVESICAL INTRAVENOUS INTRAVESICAL
Packaging size 1 1
ATC code L01DB L01DB
ATC description CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2020-06-17 2020-06-17
Estimated end date 2020-07-31 2020-07-31
Actual end date 2020-06-24 2020-06-24
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments
Health Canada comments